1. “Accentuate the negative, eliminate the positive”: Engineering allergy therapeutics to block allergic reactivity through negative signaling 
Andrew Saxon, MD, Chris Kepley, PhD, Ke Zhang, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 121, Issue 2, Pages (February 2008)
DOI: /j.jaci
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Action mode of the genetically engineered GE2 and GFD. Antigen cross-linking of 2 FcεRIs and induction of activation with enhancement of Syk and other downstream signaling molecules are diagrammed in the middle panel, where FcγRII is unoccupied. GE2 co–cross-linking FcγRIIb to FcεRI, which results in the inhibition of signaling events downstream of the FcεRI immunoreceptor tyrosine–based activation motif (ITAM), is shown in the left panel, and the cross-linking mediated by GFD is presented in the right panel. A similar mode of action has been shown for mouse GE2.16 ITIM, Immunoreceptor tyrosine–based inhibitory motif.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions